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Earlier, we reported that S6K1/mice have reduced
body fat mass, have elevated rates of lipolysis, have
severely decreased adipocyte size, and are resistant
to high fat diet (HFD)-induced obesity. Herewe report
that adipocytes of S6K1/ mice on a HFD have the
capacity to increase in size to a degree comparable
to that of wild-type (WT)mice, but not in number, indi-
cating an unexpected lesion in adipogenesis. Tracing
this lesion revealed that S6K1 is dispensable for
terminal adipocyte differentiation, but is involved in
the commitment of embryonic stem cells to early
adipocyte progenitors.We further show that absence
of S6K1 attenuates the upregulation of transcription
factors critical for commitment to adipogenesis.
These results led to the conclusion that a lack of
S6K1 impairs the generation of de novo adipocytes
when mice are challenged with a HFD, consistent
with a reduction in early adipocyte progenitors.
INTRODUCTION
Obesity is a worldwide epidemic that until recently was largely
confined to industrialized countries of the Western world, but is
now also on the ascent in urban centers of underdeveloped
nations (James et al., 2006). The key factor in promoting the
obese state is nutrient overload (Um et al., 2006) combined
with the innate drive to acquire and store fat in adipose depots
(Schwartz et al., 2003). The obese phenotype is further accentu-
ated by the body’s tendency to protect newly acquired adipose
depots in the face of deliberate reductions in food intake
(Schwartz et al., 2003). A consequence of this response is
the increased probability of initiating a number of pathologies
including insulin resistance, cardiovascular disease (Morgan
et al., 2004), and cancer (Calle and Kaaks, 2004). Given the
obesity epidemic and associated pathologies, it is critical to
understand the underlying mechanisms responsible for the
development and maintenance of normal adipose tissue.DeveAdipose depots evolved to serve as the major energy reserves
when glucose becomes limiting. Although adipocyte number
can increase throughout life, adult-onset obesity is generally
characterized by an increase in adipocyte size, whereas obesity
earlier in life involves both an increase in the size and number
of adipocytes (Kissebah and Krakower, 1994). The development
of adipose depots can be broadly divided into two stages:
(1) commitment, which involves differentiation of embryonic
stem cells (ESCs) into multipotent mesodermal stem cells, fol-
lowed by the generation of preadipocytes and (2) terminal differ-
entiation, which gives rise to adipocytes from preadipocytes and
is regulated by a network of transcription factors, including the
master regulators PPARg and C/EBPa (Gesta et al., 2007; Rosen
et al., 2002). In terminal differentiation, the identification of the
molecular components involved has been particularly assisted
by studies in genetically modified mice. In contrast, such studies
have yet to define the molecular components involved in the
commitment step (Rosen and MacDougald, 2006). However,
the recent identification of early adipocyte progenitors within
the vascular niche of adipose tissue (Tang et al., 2008; Rode-
heffer et al., 2008) opens an opportunity to analyze adipocyte
progenitors with respect to their molecular makeup and role in
adipocyte development.
An emerging component in adipogenesis is the mammalian
target of rapamycin Complex 1 (mTORC1) and its effectors, ribo-
somal protein S6 kinase 1 (S6K1) and the 4E binding proteins
(4E-BP) 1 and 2. These mTORC1 effectors appear to act as crit-
ical mediators of a nutrient/hormonal signaling network that is
involved in the development of obesity (Le Bacquer et al.,
2007; Um et al., 2004). Earlier studies showed that S6K1/
mice have reduced adipose tissue mass, have increased energy
expenditure, and are resistant to diet-induced obesity (Um et al.,
2004). The reduction in fat mass on a normal-chow diet (NCD)
was attributed to a striking decrease in adipocyte cell size due to
an increase in lipolysis (Um et al., 2004). In contrast, 4E-BP1/;
4E-BP2/ mice displayed increased sensitivity to diet-induced
obesity due to an acceleration in adipogenesis (Le Bacquer
et al., 2007). These mice also display hyperactivation of S6K1
(Le Bacquer et al., 2007), which may in part explain the
accelerated gain in adiposity. Consistent with these observa-
tions, the mTOR inhibitor rapamycin inhibits terminal adipocytelopmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier Inc. 763
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S6K1 Facilitates Commitment To Adipocytic Lineagedifferentiation in 3T3-L1 preadipocytes (El-Chaar et al., 2004;
Yeh et al., 1995) and protects mice from high fat diet (HFD)-
induced obesity (Chang et al., 2009). Moreover, the TSC1/
TSC2 tumor suppressor, which blunts mTORC1 signaling,
inhibits mouse embryonic fibroblast (MEF) differentiation into
adipocytes (Zhang et al., 2009). The inhibition by rapamycin is
reversed by expression of rapamycin-resistant mTOR, but not
by the expression of rapamycin-resistant S6K1 (Kim and Chen,
2004), despite the lean phenotype observed in S6K1-deficient
mice (Um et al., 2004). These studies have underscored the
importance of elucidating the role of S6K1 in adipogenesis.
Here, we set out to define the role of S6K1 in adipocyte cell
size regulation following an extended HFD challenge. Unexpect-
edly, we observed that in S6K1-deficient mice, adipocyte size
increased to almost the same extent as in wild-type (WT) mice,
but cell number did not, indicating a lesion adipogenesis. To
resolve whether S6K1 plays a role in the adipogenic develop-
mental processes of commitment, terminal differentiation, or
both, we took advantage of the distinct steps of adipogenesis,
which can be recapitulated in vitro by using 3T3L1 preadipo-
cytes, primary MEFs, adipose-derived stem cells (ADSCs) from
adult adipose depots, or ESCs. These studies revealed that
S6K1 function is dispensable for terminal adipocyte differentia-
tion, but plays a critical role in early adipocyte commitment.
Consistent with these findings, ADSCs isolated from the stromal
vascular fraction (SVF) of S6K1-deficient mice maintained on
a HFD, compared to WT mice, were more severely impaired in
their ability to generate new adipocytes. This finding was sup-
ported by fluorescence-activated cell sorter (FACS) analysis of
the isolated SVF from adult adipose depots of S6K1-deficient
mice, which revealed a significant reduction in early adipocyte
progenitors.
RESULTS
Adipocyte Hyperplasia Is Reduced in S6K1/ Mice
on a HFD
At birth, S6K1/ mice are 10%–15% smaller in size, with all their
tissues reduced proportionally to the same extent, except for
those that respond to insulin, including skeletal muscle, b cells,
and fat depots (Um et al., 2006). In the latter cases the effect
on tissue mass has been attributed to a reduction in cell size,
not cell number (Um et al., 2004). We reasoned that the impaired
ability of S6K1-deficient mice to accumulate fat when on a HFD
was due to a lesion in their ability to increase in cell size. To test
this possibility we analyzed hematoxylin/eosin (H&E)-stained
histological sections from the epididymal fat pads of WT and
S6K1/ mice maintained on either a NCD or HFD for 6 months.
As noted previously (Um et al., 2004), adipocytes from S6K1/
mice maintained on a NCD were dramatically reduced in size as
compared to those of WT mice (Figure 1A). Morphometric anal-
ysis showed an 70% reduction in size, whereas there was no
measurable difference in cell number (Figure 1B). In contrast,
we found an unexpected increase in adipocyte cell size in
S6K1/ mice on a HFD, such that they increased to approxi-
mately the same size as those from WT mice (Figures 1A and 1C).
This increase in cell size, unlike that of WT mice, was associated
with only a limited increase in cell number (Figures 1B and 1C).
Consistent with this result, the mass of the S6K1/ epididymal764 Developmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier Infat pad, even when normalized for the smaller mouse size,
increased less than 2-fold on a HFD, whereas that of WT mice
increased more than 3-fold (Figure 1D). Thus, the adipose tissue
of S6K1/ mice on a HFD contains fewer adipocytes (Figures
1B and 1C). These observations demonstrate an apparent lesion
in de novo adipogenesis in S6K1/ mice when challenged with
a HFD. These results also raised the possibility that elevated
levels of S6K1 activity observed in 4E-BP1/;4E-BP2/ double
knockout (DKO) mice contributes to their exhibited diet-induced
obesity (Le Bacquer et al., 2007). This was tested by crossing
4E-BP1/;4E-BP2/DKOmice withS6K1/ mice to generate
triple knockout (TKO) mice. The body weight of 4E-BP1/;
4E-BP2/ DKO mice maintained on a NCD was similar to WT
mice, whereas on a HFD they had a propensity to become obese
(Figure 1E; Le Bacquer et al., 2007). This latter effect was totally
blunted in TKO mice, whose body weight was comparable to
that of S6K1/ mice (Figure 1E). These findings indicate that
in addition to its metabolic effects on adipose tissue, S6K1 plays
a role in de novo adipogenesis.
Adipogenesis Is Impaired in S6K1/ MEFs and ADSCs
To examine the role of S6K1 in adipocyte terminal differentiation,
we took advantage of two models: the adipogenic induction of
MEFs and ADSCs (Rosen and MacDougald, 2006), the latter rep-
resenting the adherent cells from SVF of adipose tissue (Noel
et al., 2008). S6K1/ MEFs and ADSCs showed reduced adipo-
cyte differentiation, as visualized by a decrease in Oil Red O stain-
ing (Figures 2A and 2B). Quantification revealed an approximate
50% reduction in adipocyte number when compared with either
WT MEFs or WT ADSCs (Figures 2C and 2D), consistent with the
in vivo data fromS6K1/mice (Figures 1B and 1C). To determine
whether the effects of loss of S6K1 were cell autonomous, Oil Red
O staining was measured in S6K1/ and WT MEFs infected with
lentiviruses expressing either S6K1 or green fluorescent protein
(GFP), as a control. The results show that increased expression
of S6K1 had no effect on the differentiation of either cell type
(Figures 2A and 2C). Higher levels of S6K1 expression did not
interfere with kinase activation, as measured by S6K1 T389 phos-
phorylation (Figure 2E). In parallel, we used shRNAs delivered by
lentiviruses to examine the effect of S6K1 depletion on adipogen-
esis in WT ADSCs, which showed no effect on adipogenic poten-
tial, as assessed by adipocyte aP2 protein expression or Oil Red
O staining (Figures 2F and 2G). These findings suggested that
S6K1 is not required for terminal differentiation. To test this
further, we turned to mouse 3T3-L1 preadipocytes, an exten-
sively used model for the differentiation of preadipocytes into
mature adipocytes (Gesta et al., 2007; Rosen and MacDougald,
2006). Depletion of S6K1 in these cells with either of two S6K1-
shRNA lentiviruses (see Figure S1A available online) had no effect
on terminal adipocyte differentiation, as assessed by Oil Red O
staining or by expression of PPARg or Glut4 mRNAs (Figures
S1B–S1D). These data show that S6K1-deficient MEFs and
ADSCs are impaired in adipogenesis, but that the kinase is
dispensable for terminal adipocyte differentiation.
Rapamycin Treatment or S6K1 Depletion Suppresses
ESC Adipocyte Differentiation
The findings above suggest that S6K1 exerts its proadipo-
genic effects at a stage of adipogenesis earlier than terminalc.
Figure 1. Adipose Tissue of S6K1/ Mice on
a HFD Shows Adipocyte Hypertrophy but not
Hyperplasia
(A) Histological analysis of adipose tissue sections of
S6K1/ and WT mice fed on a NCD or HFD.
(B) Morphometric analysis of adipocyte cell size from NCD
epididymal white adipose tissue based on a total of
200 cells (left) and total cell number of adipocytes per fat
pad (right) from WT and S6K1/ mice (n = 3 for each
genotype).
(C) Morphometric analysis of adipocyte cell size from
HFD epididymal white adipose tissue based on a total of
200 cells (left) and total cell number of adipocytes per
fat pad (right) in WT and S6K1/ mice (n = 3 for each
genotype).
(D) Epididymal white adipose tissue total mass was
measured from WT or S6K1/ mice maintained on a
NCD or HFD. Values were normalized on the basis of
total body weight. Values in (B), (C), and (D) are given as
means ± SEM.
(E) Body weight analysis of S6K1/ (S6K1), 4E-BP1/2/
(DKO), and S6K1//4EBP1/2/ (TKO) maintained on
a NCD (left) or HFD (right) for 6 weeks (n = 6 for each geno-
type). P values are listed in Table S1.
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embryoid bodies (EBs) (Murry and Keller, 2008). EB adipogene-
sis can be divided into two stages: (1) commitment into early
adipocyte progenitors, which is dependent on all-trans retinoic
acid (RA) treatment (Bost et al., 2002), and (2) terminal adipocyte
differentiation, which can be induced by treating early adipocyte
EB progenitors with an adipogenic cocktail (Phillips et al.,
2003). To determine if mTORC1 effectors are involved in the
commitment stage, the effect of RA treatment on ribosomal
protein S6 phosphorylation, a downstream target of mTORC1/
S6K1 (Dann et al., 2007), was measured in the absence or
presence of rapamycin during this phase of the adipocyte devel-
opment [day 3 (d3) to d6] (Figure 3A). During RA-inducedDevelopmental Cell 18commitment, there was an increase in S6
S240/S244 phosphorylation, as measured by
immunohistochemistry, which was attenuated
by rapamycin (Figure 3B). To measure the
effect of rapamycin on terminal differentiation,
d6 EBs, which were incubated with rapamycin
from d3 to d6, were subjected to an adipogenic
cocktail treatment (Bost et al., 2002). The
results show that EB adipocyte terminal differ-
entiation, as assessed by Oil Red O staining
and aP2 mRNA expression, was also strongly
attenuated by rapamycin treatment during d3
to d6 (Figures 3C and 3D), indicating that
mTORC1 is critical during the commitment
phase of adipogenesis.
To assess the role of S6K1 in the commitment
phase, we depleted its levels in ESCs by using
an shRNA lentiviral vector (Figure 4A). Reduc-
tion of S6K1 levels resulted in the formation of
EBs of approximately 50% the size of control
EBs (Figure 4B), which was accounted for by
an estimated 50% reduction in cell number(Figure 4C) and not due to increased apoptosis (data not shown).
Following induction of adipocyte differentiation, and after
normalization for EB size, S6K1-shRNA-expressing EBs showed
a reduction in Oil Red O-stained adipocytes and aP2 protein
levels compared with the non-silencing shRNA (shNS) control
(Figures 4D and 4E; Figure S2B). Reintroduction of S6K1 into
S6K1-depleted ESCs (Figure S2A) rescued EB cell number
and adipocyte differentiation (Figures 4F and 4G). Consistent
with these findings, S6K1/ ESCs also display impaired com-
mitment and a reduced ability to terminally differentiate into
adipocytes (Figure S2C). These results indicate that S6K1 coop-
erates with other pathways to control the commitment stage of
adipogenesis., 763–774, May 18, 2010 ª2010 Elsevier Inc. 765
Figure 2. ReducedAdipogenesis inS6K1/
MEFs and ADSCs
(A and B) Oil Red O staining of adipocytes derived
from S6K1/ MEFs that are non-infected (LV),
infected with lentivirus overexpressing GFP
(LV-GFP), or with lentivirus overexpressing S6K1
(LV-S6K1) (A) or from ADSCs of WT or S6K1/
mouse adipose tissue (B).
(C and D) Quantification of Oil Red O-stained
adipocytes derived from either differentiated
MEFs (C) or WT and S6K1/ ADSCs (D).
(E) S6K1 was ectopically reexpressed in S6K1/
MEFs by infection with a lentivirus carrying S6K1
cDNA (LV-S6K1). Total S6K1, T389 S6K1 phos-
phorylation (P-T389 S6K1) and b-actin levels
were determined by western blot analysis.
(F) S6K1 was depleted in WT ADSCs by infection
with lentiviruses carrying either shNS or S6K1-
specific shRNAs (shS6K1). Cells were differenti-
ated into adipocytes (d9) and analyzed by western
blot to determine expression levels of total S6K1,
S240/S244 S6 phosphorylation (P-S240/244 S6),
aP2, and b-actin.
(G) Terminal adipocyte differentiation of WT and
S6K1/ ADSCs was assessed by quantification
of Oil Red O staining. Values in (C), (D), and (G)
are given as mean ± SEM (ns, not statistically
significant). See also Figure S1.
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Required for Adipogenic Commitment
RA treatment results in the increased expression of a number of
transcription factors required for early commitment to the adipo-
cytic lineage. As this step is repressed by S6K1 depletion, we
investigated whether RA induces mTORC1 signaling in ESCs
and EBs and determined the effect of depleting S6K1 on the
induction of specific transcription factors. In growing ESCs,
RA induced a transient but robust activation of S6K1 T389
phosphorylation starting at 30 min and peaking at 1hr, which
closely paralleled PKB/Akt S473 phosphorylation (Figure 5A).
RA-induced activation of S6K1 T389 phosphorylation was
inhibited by rapamycin, arguing that this is an mTORC1-depen-
dent event (Figure 5B). In contrast, rapamycin potentiated the
activation of PKB/Akt S473 phosphorylation, as well as T308
phosphorylation (Figure 5B), most likely by inhibiting the negative
feedback loop from S6K1 to PKB/Akt (Um et al., 2006). To
confirm that this response was mTOR specific, we used the
mTOR ATP-competitive inhibitor PP242 (Feldman et al., 2009),
which abolished S6K1 T389 as well as PKB/Akt T308 and
S473 phosphorylation (Figure 5B). Moreover, none of these
RA-activated responses was inhibited by actinomycin D (Fig-
ure 5B), arguing that RA does not act through transcription to
activate mTORC1 signaling. Analysis of EBs treated with RA
from d3 to d6 also revealed elevated levels of S6K1 T389
phosphorylation, which were abolished by either S6K1-shRNA
knockdown or by treatment with rapamycin (Figure 5C). To
determine the effect of S6K1 depletion on transcription factors
required for early commitment, we used cDNA microarray anal-
ysis to compare the gene expression patterns of RA-treated,
S6K1-depleted, and shNS-treated EBs. Analysis of the micro-
array results, cross-referenced with the Entrez Gene database,766 Developmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier Inshowed that a large number of proadipogenic mRNAs were
proportionally decreased following RA induction in EBs
depleted of S6K1 (Figure 5D), including KLF4 (Birsoy et al.,
2008), Lipin1 (Koh et al., 2008), and Igfbp1 (Nueda et al.,
2008; Table S2). The downregulation of a number of transcrip-
tion factors involved in early commitment to the adipocytic
lineage, including Egr2/Krox20 (Wang et al., 2009), KLF5 (Oishi
et al., 2005), C/EBPb (Chen et al., 2005), and C/EBPd (Hishida
et al., 2009), were confirmed by qRT-PCR (Figure 5E). These
data indicate that S6K1 plays a critical role in mediating RA-
induced expression of early transcription factors during adipo-
genic commitment.
S6K1 Deletion Affects Adipocyte Differentiation
of Precursor Cells from Mice Fed a HFD
As S6K1/ ESs and ADSCs are impaired in their ability to
generate preadipocytes in vitro, we asked whether this impair-
ment contributes to their resistance to HFD-induced obesity.
To test this possibility, ADSCs from mice maintained on a
NCD or HFD for 4 months were submitted to a differentiation
protocol (Experimental Procedures). The results show that de
novo adipocyte generation and the accumulation of triglycer-
ides was impaired in WT mice maintained on a HFD versus
a NCD (Figures 6A and 6B). ADSCs from S6K1/ mice main-
tained on a HFD were also impaired in their ability to generate
new adipocytes; however, as compared to S6K1/ mice main-
tained on a NCD, the effect was more severe than observed for
WT mice (Figures 6A and 6B). In neither case was there an indi-
cation of enhanced cell death (data not shown). Consistent
with the reduction in differentiated adipocytes, mRNA levels
of the preadipocyte marker Pref-1 were proportionally reduced
in isolated ADSCs from WT and S6K1/ mice (Figure 6C).c.
Figure 3. Rapamycin and S6K1 Depletion Affect Determination Step
of EB-to-Adipocyte Differentiation
(A) Schematic representation of the differentiation of WT ESCs into adipocytes
upon rapamycin treatment. EB formation (d0–d2), EBs in suspension under RA
treatment (d3–d6), adaptation to culture on gelatin-coated plates (d6–8), and
terminal differentiation of EBs into adipocytes induced by adipogenic cocktail
(d6–d22).
(B) H&E staining (left) and P-S240/244 S6 immunohistochemistry with hema-
toxylin counterstain of RA-treated EBs with or without rapamycin (rapa).
(C) Quantification of differentiated adipocytes derived from WT EBs (d22) with
or without 20 nM rapamycin (rapa) treatment in the presence of 1 mM RA (d3–
d6) with or without adipogenic differentiation inducers (d8–d22) (adipo). Oil
Red O-stained lipids were extracted, the absorbance at 510 nm (OD510) was
measured, and the value was normalized for EB number and size.
(D) Adipocyte marker aP2 mRNA levels were analyzed by qPCR and normal-
ized to 18S rRNA. Values in (C) and (D) are given as mean ± SEM.
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contribute to resistance to diet-induced obesity in S6K1/
mice.DeveEarly Adipocyte Progenitor Cells Are Reduced
in S6K1/ Mice
To address whether the early adipose stem cell population is
reduced in S6K1/ mice, we used FACS analysis to measure
the adipocyte progenitor population from SVF, as characterized
by the Lin/CD29+/CD34+/Sca+/CD24+ markers (Rodeheffer
et al., 2008). This cell population was reduced by 20% in
S6K1/ mice, as compared with WT mice (Figure 6D;
Figure S3), consistent with the deficits observed in the adipo-
genic potential of ADSC derived from S6K1/ mice (Figures
2B and 6A; Figure S3). To further characterize the reduction in
the putative adipose stem cell population, we used qRT-PCR
to examine the expression of pericyte markers (Garmy-Susini
et al., 2005; Tang et al., 2008) in total fat depots (a-Sma and
NG2) or in the SVF (PDGFRb and Vcam1). In all four cases there
was a significant reduction in the expression of each transcript in
S6K1/ versus WT mice (Figures 6E and 6F). These results indi-
cate that the loss of S6K1 leads to a reduction in the number of
early adipocyte progenitors, which plays a critical role in diet-
induced obesity (Figure 7).
DISCUSSION
S6K1 and Fat Accumulation
Given the epidemic in obesity and its associated morbidities,
a basic understanding of adipose development would greatly
enhance the development of novel therapeutics. An increase
in both adipocyte cell size and number are required for adipose
tissue growth. However, whereas adipocyte hypertrophy is
strongly influenced by diet, adipocyte hyperplasia is thought to
be more dependent on genetic background (Jo et al., 2009).
Moreover, there is continuous adipocyte turnover in humans,
with approximately 10% cell renewal per year (Spalding et al.,
2008). Therefore, adipocyte precursors, resident in fat tissue,
are poised to contribute to the expansion of adipose tissue
when faced with a nutrient challenge. However, little is known
about the precursor cells or the signaling pathways that control
their development. Earlier studies (Um et al., 2004), combined
with those presented here, support the argument that the
S6K1/ lean phenotype can be attributed to two distinct pheno-
types. First, on a NCD, S6K1/ mice, as compared to WT mice,
have elevated basal rates of lipolysis and energy expenditure,
which together contribute to a reduction in adipocyte cell size
and fat mass (Um et al., 2004). Recent studies have attributed
this effect to an increase in AMPK signaling and elevated rates
of b oxidation (Aguilar et al., 2007). Second, as shown here,
adipocytes derived from S6K1/ mice challenged with a HFD
increase in size to a level comparable to WT adipocytes, but
not in total fat mass, due to a lesion in adipogenesis. This lesion
is due to a reduction in early adipocyte progenitors (Figure 7),
which, combined with the metabolic defects, account for the
resistance to diet-induced obesity exhibited by S6K1/ mice.
S6K1 and Adipose Tissue Growth and Differentiation
That S6K1 is not critical for terminal differentiation is consistent
with the failure of rapamycin-resistant S6K1 to protect 3T3L1
adipocytes from inhibition of this response by rapamycin (Kim
and Chen, 2004). With respect to adipogenesis, it is of interest
that, in contrast to S6K1/ mice, 4E-BP1/;4E-BP2/ micelopmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier Inc. 767
Figure 4. S6K1 Is Required for Commitment of ESCs to the Adipocyte Lineage
(A) ESCs were infected with lentivirus carrying shNS or shS6K1 and stable cell lines were generated. Levels of S6K1 and b-actin protein were determined by
western blot analysis.
(B) Size measurements of EBs (d2) derived from shNS and shS6K1 lentivirus-infected ESC lines as obtained by seeding either 23 103 or 53 103 cells in suspen-
sion. (Right) Micrograph of d2 EBs.
(C) Cell numbers during EB formation by shNS and shS6K1 ESC lines at 0 hr (d0), 24 hr (d1), and 48 hr (d2).
(D) Oil Red O staining of differentiated adipocytes derived from shNS and shS6K1 EBs.
(E) Adipocyte differentiation was assessed by spectrophotometric detection at 510 nm (OD510) of Oil Red O in extracts from EBs infected with shNS- or shS6K1-
containing lentiviruses. Values were normalized to EB size and number.
(F) S6K1 was ectopically reexpressed in shS6K1 ESCs (shS6K1+LVS6K1) and cell number was determined during EB formation at the 24 hr time point.
(G) Adipocyte differentiation assessed, as in (E), by measuring Oil Red O stain in cell extracts and normalized according to EB size and number. Values in (B), (C),
(E), (F), and (G) are given as mean ± SEM. See also Figure S2.
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in vitro, which is paralleled by increased levels of C/EBPd
mRNA and S6K1 hyperactivation (Le Bacquer et al., 2007).
S6K1 hyperactivation is most likely due to increased levels of
available mTORC1, suggesting that the 4E-BPs not only
suppress initiation factor eIF4E but also indirectly suppress
S6K1 activation by competing for available mTORC1 via raptor
binding to their TOS motifs (Schalm and Blenis, 2002). This
hypothesis is consistent with our earlier findings that overex-768 Developmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier Inpression of dominant-interfering S6K1 not only blocked reporter
S6K1 activation but also suppressed reporter 4E-BP1 phosphor-
ylation (von Manteuffel et al., 1997). Moreover, these findings
suggest a dominant role for S6K1 versus 4E-BP1 and 4E-BP2
in adipogenesis as S6K1//4E-BP1//2/ mice have an
adipogenic phenotype equivalent to S6K1-deficient mice
(Figure 1E). This model also fits with recent data demonstrating
that mice harboring an adipose-specific deletion of raptor are
lean and have increased mitochondrial respiration (Polak et al.,c.
Figure 5. RA Treatment Activates S6K1 Phosphorylation in ESCs and EBs
(A) (Left) ESCs were treated with 10 mM RA for 2 hr. S6K1 T389 and PKB/Akt S473 phosphorylation were measured by western blot analysis and b-actin was used
as a protein-loading control.
(B) ESCs were pretreated for 15 min with 20 nM rapamycin (rapa), 8 mM PP242, or 5 mg/ml actinomycin D (ActD), and then stimulated with 10 mM RA for an
additional 45 min. Levels of P-T389 S6K1, P-S473 PKB/Akt, P-T308 PKB/Akt, and P-S240/244 S6 were detected by western blot analysis. mTOR was used
as protein-loading control.
(C) EBs formed from the shNS ESC line (ns) or shS6K1ESC line (kd) were treated with 1 mM RA for 3 days (d3–d6). Total S6K1, P-T389 S6K1, and P-S240/244 S6
were determined by western blot analysis in d6 EBs, with b-actin used as a protein-loading control.
(D) Number of adipogenesis-related genes upregulated or downregulated in microarray analyses of RA-treated shNS and shS6K1 EBs (see Experimental Proce-
dures).
(E) Expression levels of early adipogenic marker genes Krox20/Egr2, KLF5, C/EBPb, and C/EBPd. Total RNA was prepared from RA-treated shNS EBs (d6RA
shNS) or shS6K1 EBs (d6RA shS6K1) and analyzed by qPCR. The expression values were normalized to 18S rRNA levels. Values in (D) are given as mean ±
SEM. See also Table S2.
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S6K1 Facilitates Commitment To Adipocytic Lineage2008) and that rapamycin treatment protects mice from HFD-
induced obesity by reducing lipid accumulation (Chang et al.,
2009). Taken together, these data suggest that 4E-BP1 and
4E-BP2 play a central role in terminal adipocyte differentiation,
whereas S6K1 plays a critical role in precursor cell commitment.
In humans, the ability of ADSCs to differentiate into mature
adipocytes is negatively correlated with both body mass index
and adipocyte cell size (Isakson et al., 2009). Our results in WT
mice maintained on a HFD are consistent with this finding,
revealing a reduction in ADSCs and the marker Pref-1. Recently,
two groups pointed to the perivascular adipose tissue as a nicheDevefor ADSC precursors, which appear to be pericytes or mural cells
(da Silva Meirelles et al., 2008; Rodeheffer et al., 2008; Tang
et al., 2008). Consistent with this finding, we observed a reduc-
tion in the pericyte markers a-Sma, NG2, Vcam1, and PDGFRb
in S6K1/ adipose tissue. Taken together, our studies suggest
that S6K1 is a modulator of cell fate at very early stages of devel-
opment and that absence of the gene in vivo acts to suppress
diet-induced obesity by preventing the increase of white adipose
tissue mass (Figure 7). Interestingly, similar to ADSCs, rapamy-
cin inhibits the differentiation of primary mouse bone marrow
stromal cells into osteoblasts (Singha et al., 2008). However,lopmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier Inc. 769
Figure 6. S6K1 Is Required for the Generation and Differentiation of Adipocyte Precursor Cells in Adipose Tissue of Mice Exposed to a HFD
(A) Oil Red O staining of differentiated adipocytes from WT or S6K1/ ADSC cells derived from adipose tissue of 6-month-old mice maintained either on a NCD
or a HFD (n = 3 mice of each genotype).
(B) Quantification of total triglyceride content from differentiated cells, normalized to total DNA content. Values are given as mean ± SD.
(C) Expression levels of Pref-1 marker in ADSCs.
(D) Sorting of Lin/CD29+/Sca1+/CD34+/CD24+ cells (CD24+) from SVFs of WT and S6K1/ mice.
(E) Expression levels of pericyte markers a-Sma and NG2 in total fat depots.
(F) Expression levels of PDGFRb and Vcam1 in SVFs.
(E and F) Data obtained by qPCR measurements and normalized to 18S rRNA levels (values given as mean ± SEM). See also Figure S3.
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S6K1 Facilitates Commitment To Adipocytic Lineagealthough S6K1/ mice remain lean as a function of age, they
display an attenuation of age-dependent loss of cancellous
bone (Selman et al., 2009). This raises the possibility that
inhibitors of the S6K1 branch of mTORC1 signaling may be
useful in the treatment of obesity and associated diseases and
may be protective against age-related pathologies such as oste-
oporosis.
S6K1 and Stem Cell Commitment to the Adipocyte
Lineage
Given the central role of stem cell biology in tissue replacement,
it has become important to understand the underlying molecular
mechanisms that coordinate the distinct cell differentiation770 Developmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier Inprograms involved in tissue development and remodeling (Xu
et al., 2008). Here we show that absence of S6K1 plays a critical
role in modulating the lineage specificity of early adipocyte
progenitors by limiting the number of preadipocytes during
development and throughout adult life. Consistent with this
finding, the two upstream activating S6K1 kinases, mTORC1
and the phosphoinositide-dependent protein kinase (PDK1),
are known to regulate ESC growth, stem cell self-renewal,
embryo development, and germ layer differentiation (Bone and
Welham, 2007; Gangloff et al., 2004; Takahashi et al., 2005;
Zhou et al., 2009). The data presented here demonstrate that
S6K1 is involved in the control of proliferation and differentiation
of stem cells. In agreement with this, we (Gangloff et al., 2004)c.
Figure 7. Model Depicting the Effect of
S6K1 Loss on Adipogenesis in Mice Main-
tained on a NCD or When Challenged with
a HFD
See text for details.
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S6K1 Facilitates Commitment To Adipocytic Lineageand others (Murakami et al., 2004) demonstrated that tropho-
blasts and ESCs, the latter isolated from the blastocyst inner
cell mass, fail to proliferate when derived from mTOR/
embryos. That these effects are elicited through mTORC1 is sup-
ported by recent studies demonstrating that rapamycin treat-
ment of ESCs inhibits EB cell proliferation, resulting in reduced
EB size and cellularity (Sampath et al., 2008). However, these
effects were largely attributed to the 4E-BPs, whereas our
studies suggest they are due to S6K1. This conclusion is consis-
tent with the decreased cell proliferation and total EB size seen in
ESCs deficient for PDK1, an upstream effector of S6K1, but not
of the 4E-BPs (Bone and Welham, 2007). The effects of PDK1
were initially attributed to its role as a downstream effector of
class IA PI3K (Bone and Welham, 2007; Riley et al., 2006).
However, it should be noted that PDK1 phosphorylation and
activation of S6K1 does not require increased phosphatidylinosi-
tide-3,4,5-P3 (Pullen et al., 1998). Instead, it requires only
mTORC1 phosphorylation at S6K1 T389, which acts as a dock-
ing site for PDK1 (Biondi et al., 2001). Moreover, mTORC1 acti-
vation and early embryo development are driven by nutrients,
such as amino acids (Gangloff et al., 2004), which can act inde-
pendently of growth factors and class IA PI3K to drive full
mTORC1 activation (Hara et al., 1998). Indeed, stimulation of
mTORC1, by amino acids alone, drives the expression of
PPARg, a master regulator of adipogenesis (Kim and Chen,
2004). These findings raise the possibility that the effects of
S6K1 on EB formation may not only rely on class 1A PI3K (see
below) but also on nutrient input to mTORC1.
A potential mediator of S6K1 activation during early adipocyte
development is RA (Dani et al., 1997). It has been shown that
ESC commitment to the adipocyte lineage is dependent on
RA activation of ERK and GSK3 (Bost et al., 2002; Monteiro
et al., 2009). Upon RA treatment, S6K1 T389 phosphorylation
is increased in control EBs and this activation is suppressed
by rapamycin (Figure 6B), arguing that this is an mTORC1-
dependent event. Moreover, we demonstrate that the RA-Developmental Cell 18, 763–induced expression of early adipogenic
transcription factors, including Krox20,
KLF5, C/EBPb, and C/EBPd, is reduced
in S6K1-depleted EBs, as compared
with WT. The two isoforms of S6K1,
which are generated from the same tran-
script through alternative translational
initiation start sites (Montagne and
Thomas, 2004), can localize to the
nucleus (Panasyuk et al., 2006) and have
been implicated in the control of mRNA
transcription and processing at multiple
levels. S6K1 has been shown to directly
phosphorylate and regulate a number of
transcription factors including cAMP-responsive element modulator t (de Groot et al., 1994) and
estrogen receptor a (Yamnik et al., 2009), as well as the RNA
polymerase 1 upstream binding factor (Hannan et al., 2003).
However, S6K1 can also act indirectly on transcription, as we
have recently demonstrated in the case of stabilization of c-
Myc through the phosphorylation and inactivation of GSK3b (Gu-
lati et al., 2008) and as others have shown through the regulation
of the exon junction complex (Ma et al., 2008). Present studies
are aimed at elucidating the level at which S6K1 exerts an effect
on the early adipogenic transcription factors.
In summary, we show that, in addition to the metabolic effects
of S6K1 depletion on adipose tissue development, S6K1 and
mTORC1 signaling pathway play a major role in early stages of
adipogenesis by affecting the ability of ESCs to commit to the
adipocytic lineage. These findings suggest that pharmacological
intervention in the nutrient-sensing mTORC1 pathway is a rele-
vant and promising target in tackling the epidemic in obesity,
as recently suggested by others (Chang et al., 2009). Our results
also suggest that the mTORC1 signaling pathway is critical in
stem cell biology and in modulating differentiation programs,
such that augmenting the activity of this pathway could be effica-
cious in regenerative medicine.
EXPERIMENTAL PROCEDURES
Mice
S6-kinase-deficient mice, created previously by homologous recombination,
were genotyped as described previously (Shima et al., 1998) and kept in a
hybrid 129/svXBalb/C or inbred C57Bl/6 background. Eif4ebp1 and Eif4ebp2
mutant mice were generated as previously described (Banko et al., 2005;
Tsukiyama-Kohara et al., 2001). For the generation of TKO mice, S6K1/
(129/svXBalb/C) were crossed with 4E-BP1/2 DKO (C57BL/6XDBA/2J).
Mice were housed in plastic cages and maintained at 22C with a 12 hr
dark, 12 hr light schedule. Eight-week-old animals were fed either a control
NCD (D12450B; 20% protein, 70% carbohydrate, and 10% fat) or a HFD
(D12492; 20% protein, 20% carbohydrate, and 60% fat) for 16 weeks
(Research Diets Inc.). All studies were Institutional Animal Care and Use
Committee approved and performed according to the ethical guidelines of774, May 18, 2010 ª2010 Elsevier Inc. 771
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S6K1 Facilitates Commitment To Adipocytic Lineagethe University of Cincinnati and the McGill University Animal Resource
Center.
Histology and Morphometric Analysis of Tissues
Adipose tissue was analyzed by examining H&E-stained histological sections
as previously described (Picard et al., 2002). Morphometric analysis of epidid-
ymal WAT was performed by measuring 200 or more cells from at least three
H&E sections per mouse and genotype (n = 3 mice) with the aid of ImageJ soft-
ware (NIH) and AdiposeTissueAnalyzer v2.1 (Tiago Ferreira). To quantify cell
number, adipocytes were isolated from 100 mg of adipose tissue by using
2 mg/ml collagenase type II-S (Sigma-Aldrich) digestion buffer and counted
using a hemacytometer. Results were normalized to the fat-pad weight of
each mouse (n = 3). Data are presented as the mean ± SEM.
Western Blot Analysis and Antibodies
Cells were harvested in lysis buffer. Proteins were resolved by SDS-PAGE
and transferred to ECL-Hybond nitrocellulose membranes (GE healthcare).
Antibodies against total S6K1 were purchased from BD Biosciences and
antibodies against b-actin, mTOR, Thr389-phosphorylated S6K1, Ser473
and Thr-308 phospho-PKB/Akt, S6, and Ser240/244-phosphorylated S6
were purchased from Cell Signaling. The aP2 antibody was purchased from
Cayman Chemical. See protocol details in Supplemental Experimental
Procedures.
Adipocyte Differentiation of Primary MEFs and ADSCs
Primary MEFs (passage 0 or 1) from 13.5- to 14.5-day-old embryos were
grown to confluence (d0) in maintenance medium (DMEM containing 10%
FBS). Adipocyte differentiation was induced for 2 days by treating confluent
cells for 48 hr in differentiation medium supplemented with 500 mM 3-isobu-
tyl-1-methylxanthine (Sigma-Aldrich), 1 mM dexamethasone (Sigma-Aldrich),
and 10 mg/ml insulin (Sigma-Aldrich). After the induction period, the medium
was replaced with differentiation medium supplemented with 1 mM ciglitazone
(Sigma-Aldrich), which was then changed every second day. After eight addi-
tional days in differentiation medium (d10), the cells exhibited a fully differen-
tiated phenotype with massive accumulation of multilocular fat droplets. For
ADSC differentiation, adipocytes and their precursor cells were isolated from
WT and S6K1/ epididymal and inguinal white adipose tissue by collagenase
digestion, as previously described (Prunet-Marcassus et al., 2006). After
centrifugation, cells from the pellet were cultured on tissue culture plates. Cells
attaching to the plates constitute ADSCs, which were trypsinized and seeded
at the same concentration. Confluent cells were differentiated by adding
10 mg/ml insulin, 1 nM 3,30,5-triiodo- L-thyronine (T3; Sigma-Aldrich), and
125 mM indomethacin (Sigma-Aldrich). The medium was changed every
2 days and fully differentiated cells were analyzed after 9 days. Three to four
mice of each genotype were used per experiment. Experiments were carried
out in duplicate.
ESC Growth and Differentiation
C57BL/6J ESCs were a gift from J. Neuman, and CCE cells, a mouse ESC line
derived from the 129/Sv mouse strain, were donated by Stemcell Technolo-
gies. ESCs were grown in DMEM supplemented with 15% ES FCS (GIBCO),
13 non-essential amino acids (Sigma-Aldrich), 50 mM b-mercaptoethanol
(Sigma-Aldrich), 0.1% sodium bicarbonate (Sigma-Aldrich), 100 IU/ml peni-
cillin, 100 mg/ml streptomycin (Hyclone), and 1000 U/ml murine leukemia
inhibitory factor (LIF) (ESGRO; Chemicon) (ES cell medium). ES cells were
treated with either 20 nM rapamycin, 8 mM PP242 (from K. Shokat, University
of California, San Francisco), or 5 mg/ml actinomycin D (Sigma-Aldrich). Adipo-
cyte differentiation was performed as described in Dani et al. (1997). Briefly,
1–5 3103 cells were seeded (d0) in hanging drops on bacteriological plate
lids and allowed to form EBs for 2 days in ES cell medium without LIF. EBs
were then transferred to plates and kept in suspension. After 24 hr (d3), the
EBs were incubated with 1 mM all-trans RA (Sigma-Aldrich) for 3 days (until
d6), with or without 20 nM rapamycin. After RA treatment, the spherical EBs
were further cultured on gelatin-coated tissue culture plates for the induction
of adipogenic differentiation. After 48 hr of adaptation in maintenance medium
(d8 from start), 0.5 mg/ml insulin and 2 nM T3 was added to the medium to
initiate adipocyte differentiation. Cells were kept in differentiation medium
for two additional weeks, with fresh medium added every 2 days.772 Developmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier InOil Red O staining and triglyceride content measurement is described in
Supplemental Experimental Procedures.
Image Analysis
Axion Vision 4.0 software was used to count cells, to quantify adipocyte
number by Oil Red O staining, to determine EB size by calculating area and
diameter, and to measure Oil Red O staining intensity.
Isolation of RNA, qRT-PCR, and Microarray Analyses
RNA extraction, qRT-PCR, and microarray analyses of gene expression were
performed as described in the Supplemental Experimental Procedures.
Statistical Analysis
Data are presented as mean ± SEM. The effects were analyzed by one-way
ANOVA or two-tailed unpaired t test. Analyses were performed using Graph-
Pad Prism software. Differences were considered to be statistically significant
at p < 0.05 versus WT.
ACCESSION NUMBERS
Microarray analyses of gene expression have been deposited in the Gene
Expression Omnibus under accession number GSE20349.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.devcel.2010.02.018.
ACKNOWLEDGMENTS
The authors want to thank V. Zimmerman for technical assistance,
J.C. Neumann for providing mouse ESCs, and C. Gallo and D. Plas for assis-
tance with the FACS analysis. We are grateful to K. Shokat for kindly providing
PP242 as well as to M. Medvedovic, J. Chen, and B. Aronow for microarray
analysis. The microarray data analysis and management were funded by
National Institute of Environmental Health Sciences grant P30-ES006096.
We would also like to thank G.M. Keller, O. MacDougald, and C.R. Kahn for
fruitful discussions as well as Y. Zheng, M. Daston, and G. Doerman for their
critical reading of the manuscript, editing, and drawing of figures, respectively.
These studies were supported by a fellowship on adipogenesis from Procter
and Gamble Pharmaceuticals to L.S.C.; National Institutes of Health grants
R01DK073802 and U01CA141464 to S.C.K. and G.T., who is the John and
Gladys Strauss Professor of Cancer Biology; and Canadian Institutes of Health
Research grant MOP-37968 to N.S., who is a Howard Hughes Medical Insti-
tute International Research Scholar and a James McGill Professor. I.T. is
a Special Fellow of the Leukemia and Lymphoma Society (USA).
Received: August 27, 2009
Revised: January 4, 2010
Accepted: February 26, 2010
Published: May 17, 2010
REFERENCES
Aguilar, V., Alliouachene, S., Sotiropoulos, A., Sobering, A., Athea, Y., Djouadi,
F., Miraux, S., Thiaudiere, E., Foretz, M., Viollet, B., et al. (2007). S6 kinase
deletion suppresses muscle growth adaptations to nutrient availability by
activating AMP kinase. Cell Metab. 5, 476–487.
Banko, J.L., Poulin, F., Hou, L., DeMaria, C.T., Sonenberg, N., and Klann, E.
(2005). The translation repressor 4E-BP2 is critical for eIF4F complex
formation, synaptic plasticity, and memory in the hippocampus. J. Neurosci.
25, 9581–9590.
Biondi, R.M., Kieloch, A., Currie, R.A., Deak, M., and Alessi, D.R. (2001). The
PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but
not PKB. EMBO J. 20, 4380–4390.c.
Developmental Cell
S6K1 Facilitates Commitment To Adipocytic LineageBirsoy, K., Chen, Z., and Friedman, J. (2008). Transcriptional regulation of
adipogenesis by KLF4. Cell Metab. 7, 339–347.
Bone, H.K., and Welham, M.J. (2007). Phosphoinositide 3-kinase signalling
regulates early development and developmental haemopoiesis. J. Cell Sci.
120, 1752–1762.
Bost, F., Caron, L., Marchetti, I., Dani, C., Le Marchand-Brustel, Y., and
Binetruy, B. (2002). Retinoic acid activation of the ERK pathway is required
for embryonic stem cell commitment into the adipocyte lineage. Biochem. J.
361, 621–627.
Calle, E.E., and Kaaks, R. (2004). Overweight, obesity and cancer: epidemio-
logical evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579–591.
Chang, G.R., Chiu, Y.S., Wu, Y.Y., Chen, W.Y., Liao, J.W., Chao, T.H., and
Mao, F.C. (2009). Rapamycin protects against high fat diet-induced obesity
in C57BL/6J mice. J. Pharmacol. Sci. 109, 496–503.
Chen, Z., Torrens, J.I., Anand, A., Spiegelman, B.M., and Friedman, J.M.
(2005). Krox20 stimulates adipogenesis via C/EBPbeta-dependent and
-independent mechanisms. Cell Metab. 1, 93–106.
da Silva Meirelles, L., Caplan, A.I., and Nardi, N.B. (2008). In search of the
in vivo identity of mesenchymal stem cells. Stem Cells 26, 2287–2299.
Dani, C., Smith, A.G., Dessolin, S., Leroy, P., Staccini, L., Villageois, P.,
Darimont, C., and Ailhaud, G. (1997). Differentiation of embryonic stem cells
into adipocytes in vitro. J. Cell Sci. 110, 1279–1285.
Dann, S.G., Selvaraj, A., and Thomas, G. (2007). mTOR Complex1-S6K1
signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol.
Med. 13, 252–259.
de Groot, R.P., Ballou, L.M., and Sassone-Corsi, P. (1994). Positive regulation
of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative
route to mitogen-induced gene expression. Cell 79, 81–91.
El-Chaar, D., Gagnon, A., and Sorisky, A. (2004). Inhibition of insulin signaling
and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs
eIF4E-BP1. Int. J. Obes. Relat. Metab. Disord. 28, 191–198.
Feldman, M.E., Apsel, B., Uotila, A., Loewith, R., Knight, Z.A., Ruggero, D., and
Shokat, K.M. (2009). Active-site inhibitors of mTOR target rapamycin-resistant
outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38.
Gangloff, Y.G., Mueller, M., Dann, S.G., Svoboda, P., Sticker, M., Spetz, J.F.,
Um, S.H., Brown, E.J., Cereghini, S., Thomas, G., et al. (2004). Disruption of
the mouse mTOR gene leads to early postimplantation lethality and prohibits
embryonic stem cell development. Mol. Cell. Biol. 24, 9508–9516.
Garmy-Susini, B., Jin, H., Zhu, Y., Sung, R.J., Hwang, R., and Varner, J. (2005).
Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and
mural cells is required for blood vessel maturation. J. Clin. Invest. 115,
1542–1551.
Gesta, S., Tseng, Y.H., and Kahn, C.R. (2007). Developmental origin of fat:
tracking obesity to its source. Cell 131, 242–256.
Gulati, P., Gaspers, L.D., Dann, S.G., Joaquin, M., Nobukuni, T., Natt, F.,
Kozma, S.C., Thomas, A.P., and Thomas, G. (2008). Amino acids activate
mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab. 7, 456–465.
Hannan, K.M., Brandenburger, Y., Jenkins, A., Sharkey, K., Cavanaugh, A.,
Rothblum, L., Moss, T., Poortinga, G., McArthur, G.A., Pearson, R.B., et al.
(2003). mTOR-dependent regulation of ribosomal gene transcription requires
S6K1 and is mediated by phosphorylation of the carboxy-terminal activation
domain of the nucleolar transcription factor UBF. Mol. Cell. Biol. 23,
8862–8877.
Hara, K., Yonezawa, K., Weng, Q.P., Kozlowski, M.T., Belham, C., and
Avruch, J. (1998). Amino acid sufficiency and mTOR regulate p70 S6 kinase
and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273,
14484–14494.
Hishida, T., Nishizuka, M., Osada, S., and Imagawa, M. (2009). The role of
C/EBPdelta in the early stages of adipogenesis. Biochimie 91, 654–657.
Isakson, P., Hammarstedt, A., Gustafson, B., and Smith, U. (2009). Impaired
preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor
necrosis factor-alpha, and inflammation. Diabetes 58, 1550–1557.
James, W.P., Rigby, N., and Leach, R. (2006). Obesity and the metabolic
syndrome: the stress on society. Ann. NY Acad. Sci. 1083, 1–10.DeveJo, J., Gavrilova, O., Pack, S., Jou, W., Mullen, S., Sumner, A.E., Cushman,
S.W., and Periwal, V. (2009). Hypertrophy and/or hyperplasia: dynamics of
adipose tissue growth. PLoS Comput. Biol. 5, e1000324.
Kim, J.E., and Chen, J. (2004). Regulation of peroxisome proliferator-activated
receptor-gamma activity by mammalian target of rapamycin and amino acids
in adipogenesis. Diabetes 53, 2748–2756.
Kissebah, A.H., and Krakower, G.R. (1994). Regional adiposity and morbidity.
Physiol. Rev. 74, 761–811.
Koh, Y.K., Lee, M.Y., Kim, J.W., Kim, M., Moon, J.S., Lee, Y.J., Ahn, Y.H., and
Kim, K.S. (2008). Lipin1 is a key factor for the maturation and maintenance of
adipocytes in the regulatory network with CCAAT/enhancer-binding protein
alpha and peroxisome proliferator-activated receptor gamma 2. J. Biol.
Chem. 283, 34896–34906.
Le Bacquer, O., Petroulakis, E., Paglialunga, S., Poulin, F., Richard, D.,
Cianflone, K., and Sonenberg, N. (2007). Elevated sensitivity to diet-induced
obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J. Clin.
Invest. 117, 387–396.
Ma, X.M., Yoon, S.O., Richardson, C.J., Julich, K., and Blenis, J. (2008). SKAR
links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation
efficiency of spliced mRNAs. Cell 133, 303–313.
Montagne, J., and Thomas, G. (2004). S6K integrates nutrient and mitogenic
signals to control cell growth. In In Cell Growth: Control of Cell Size. Cold
Spring Harbor Monograph Series #42, M. Hall, M. Raff, and G. Thomas, eds.
(Cold Spring Harbor, NY: Cold Spring Laboratory Press), pp. 265–298.
Monteiro, M.C., Wdziekonski, B., Villageois, P., Vernochet, C., Iehle, C., Billon,
N., and Dani, C. (2009). Commitment of mouse embryonic stem cells to the
adipocyte lineage requires retinoic acid receptor beta and active GSK3.
Stem Cells Dev. 18, 457–463.
Morgan, K.P., Kapur, A., and Beatt, K.J. (2004). Anatomy of coronary disease
in diabetic patients: an explanation for poorer outcomes after percutaneous
coronary intervention and potential target for intervention. Heart 90, 732–738.
Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F.,
Kiyama, H., Yonezawa, K., and Yamanaka, S. (2004). mTOR is essential for
growth and proliferation in early mouse embryos and embryonic stem cells.
Mol. Cell. Biol. 24, 6710–6718.
Murry, C.E., and Keller, G. (2008). Differentiation of embryonic stem cells to
clinically relevant populations: lessons from embryonic development. Cell
132, 661–680.
Noel, D., Caton, D., Roche, S., Bony, C., Lehmann, S., Casteilla, L., Jorgensen,
C., and Cousin, B. (2008). Cell specific differences between human adipose-
derived and mesenchymal-stromal cells despite similar differentiation poten-
tials. Exp. Cell Res. 314, 1575–1584.
Nueda, M.L., Garcia-Ramirez, J.J., Laborda, J., and Baladron, V. (2008). dlk1
specifically interacts with insulin-like growth factor binding protein 1 to modu-
late adipogenesis of 3T3-L1 cells. J. Mol. Biol. 379, 428–442.
Oishi, Y., Manabe, I., Tobe, K., Tsushima, K., Shindo, T., Fujiu, K., Nishimura,
G., Maemura, K., Yamauchi, T., Kubota, N., et al. (2005). Kruppel-like tran-
scription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab.
1, 27–39.
Panasyuk, G., Nemazanyy, I., Zhyvoloup, A., Bretner, M., Litchfield, D.W.,
Filonenko, V., and Gout, I.T. (2006). Nuclear export of S6K1 II is regulated
by protein kinase CK2 phosphorylation at Ser-17. J. Biol. Chem. 281,
31188–31201.
Phillips, B.W., Vernochet, C., and Dani, C. (2003). Differentiation of embryonic
stem cells for pharmacological studies on adipose cells. Pharmacol. Res. 47,
263–268.
Picard, F., Gehin, M., Annicotte, J., Rocchi, S., Champy, M.F., O’Malley, B.W.,
Chambon, P., and Auwerx, J. (2002). SRC-1 and TIF2 control energy balance
between white and brown adipose tissues. Cell 111, 931–941.
Polak, P., Cybulski, N., Feige, J.N., Auwerx, J., Ruegg, M.A., and Hall, M.N.
(2008). Adipose-specific knockout of raptor results in lean mice with enhanced
mitochondrial respiration. Cell Metab. 8, 399–410.lopmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier Inc. 773
Developmental Cell
S6K1 Facilitates Commitment To Adipocytic LineagePrunet-Marcassus, B., Cousin, B., Caton, D., Andre, M., Penicaud, L., and
Casteilla, L. (2006). From heterogeneity to plasticity in adipose tissues: site-
specific differences. Exp. Cell Res. 312, 727–736.
Pullen, N., Dennis, P.B., Andjelkovic, M., Dufner, A., Kozma, S.C., Hemmings,
B.A., and Thomas, G. (1998). Phosphorylation and activation of p70s6k by
PDK1. Science 279, 707–710.
Riley, J.K., Carayannopoulos, M.O., Wyman, A.H., Chi, M., and Moley, K.H.
(2006). Phosphatidylinositol 3-kinase activity is critical for glucose metabolism
and embryo survival in murine blastocysts. J. Biol. Chem. 281, 6010–6019.
Rodeheffer, M.S., Birsoy, K., and Friedman, J.M. (2008). Identification of white
adipocyte progenitor cells in vivo. Cell 135, 240–249.
Rosen, E.D., and MacDougald, O.A. (2006). Adipocyte differentiation from the
inside out. Nat. Rev. Mol. Cell Biol. 7, 885–896.
Rosen, E.D., Hsu, C.H., Wang, X., Sakai, S., Freeman, M.W., Gonzalez, F.J.,
and Spiegelman, B.M. (2002). C/EBPalpha induces adipogenesis through
PPARgamma: a unified pathway. Genes Dev. 16, 22–26.
Sampath, P., Pritchard, D.K., Pabon, L., Reinecke, H., Schwartz, S.M., Morris,
D.R., and Murry, C.E. (2008). A hierarchical network controls protein transla-
tion during murine embryonic stem cell self-renewal and differentiation. Cell
Stem Cell 2, 448–460.
Schalm, S.S., and Blenis, J. (2002). Identification of a conserved motif required
for mTOR signaling. Curr. Biol. 12, 632–639.
Schwartz, M.W., Woods, S.C., Seeley, R.J., Barsh, G.S., Baskin, D.G., and
Leibel, R.L. (2003). Is the energy homeostasis system inherently biased toward
weight gain? Diabetes 52, 232–238.
Selman, C., Tullet, J.M., Wieser, D., Irvine, E., Lingard, S.J., Choudhury, A.I.,
Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009).
Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.
Science 326, 140–144.
Shima, H., Pende, M., Chen, Y., Fumagalli, S., Thomas, G., and Kozma, S.C.
(1998). Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype
and a new functional S6 kinase. EMBO J. 17, 6649–6659.
Singha, U.K., Jiang, Y., Yu, S., Luo, M., Lu, Y., Zhang, J., and Xiao, G. (2008).
Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1
cells and primary mouse bone marrow stromal cells. J. Cell. Biochem. 103,
434–446.
Spalding, K.L., Arner, E., Westermark, P.O., Bernard, S., Buchholz, B.A.,
Bergmann, O., Blomqvist, L., Hoffstedt, J., Naslund, E., Britton, T., et al.
(2008). Dynamics of fat cell turnover in humans. Nature 453, 783–787.774 Developmental Cell 18, 763–774, May 18, 2010 ª2010 Elsevier InTakahashi, K., Murakami, M., and Yamanaka, S. (2005). Role of the phosphoi-
nositide 3-kinase pathway in mouse embryonic stem (ES) cells. Biochem. Soc.
Trans. 33, 1522–1525.
Tang, W., Zeve, D., Suh, J.M., Bosnakovski, D., Kyba, M., Hammer, R.E.,
Tallquist, M.D., and Graff, J.M. (2008). White fat progenitor cells reside in the
adipose vasculature. Science 322, 583–586.
Tsukiyama-Kohara, K., Kohara, P.F., De, M., Maria, C.T., Cheng, A., Wu, Z.,
Gingras, A.C., Katsume, A., Elchebly, M., Spiegelman, B.M., et al. (2001).
Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1.
Nat. Med. 7, 1128–1132.
Um, S.H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M.,
Fumagalli, S., Allegrini, P.R., Kozma, S.C., Auwerx, J., et al. (2004). Absence
of S6K1 protects against age- and diet-induced obesity while enhancing
insulin sensitivity. Nature 431, 200–205.
Um, S.H., D’Alessio, D., and Thomas, G. (2006). Nutrient overload, insulin
resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 3, 393–402.
von Manteuffel, S.R., Dennis, P.B., Pullen, N., Gingras, A.C., Sonenberg, N.,
and Thomas, G. (1997). The insulin-induced signalling pathway leading to S6
and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapa-
mycin-sensitive point immediately upstream of p70s6k. Mol. Cell. Biol. 17,
5426–5436.
Wang, W., Huang, L., Huang, Y., Yin, J.W., Berk, A.J., Friedman, J.M., and
Wang, G. (2009). Mediator MED23 links insulin signaling to the adipogenesis
transcription cascade. Dev. Cell 16, 764–771.
Xu, Y., Shi, Y., and Ding, S. (2008). A chemical approach to stem-cell biology
and regenerative medicine. Nature 453, 338–344.
Yamnik, R.L., Digilova, A., Davis, D.C., Brodt, Z.N., Murphy, C.J., and Holz,
M.K. (2009). S6 kinase 1 regulates estrogen receptor alpha in control of breast
cancer cell proliferation. J. Biol. Chem. 284, 6361–6369.
Yeh, W.C., Bierer, B.E., and McKnight, S.L. (1995). Rapamycin inhibits clonal
expansion and adipogenic differentiation of 3T3-L1 cells. Proc. Natl. Acad. Sci.
USA 92, 11086–11090.
Zhang, H.H., Huang, J., Duvel, K., Boback, B., Wu, S., Squillace, R.M., Wu,
C.L., and Manning, B.D. (2009). Insulin stimulates adipogenesis through the
Akt-TSC2-mTORC1 pathway. PLoS ONE 4, e6189.
Zhou, J., Su, P., Wang, L., Chen, J., Zimmermann, M., Genbacev, O., Afonja,
O., Horne, M.C., Tanaka, T., Duan, E., et al. (2009). mTOR supports long-term
self-renewal and suppresses mesoderm and endoderm activities of human
embryonic stem cells. Proc. Natl. Acad. Sci. USA 106, 7840–7845.c.
